Latest news with #LifeSciences
Business Wire
a day ago
- Business
- Business Wire
Trinity Life Sciences Unveils Critical Insights for Navigating the Path From Initial Generative AI Adoption to Full-Scale Transformation
WALTHAM, Mass.--(BUSINESS WIRE)-- Trinity Life Sciences, the leader in advisory, insights and analytics for the life sciences industries, discusses the journey to achieving successful transformation with generative AI (GenAI) in a new white paper, entitled Technology with a Point of View: Encoding Life Sciences Expertise with AI. GenAI is a technological disruption with significant potential to revolutionize biopharmaceutical commercialization across functions and use cases by: Changing how life sciences companies find, organize and use the reams of information they handle every day Measurably improving the speed of developing insights and reducing duplicative work Handling complex data and generating sophisticated outputs GenAI can be highly effective—and it can also create frustration and disappointment when deployed ineffectively. Public failures of hastily built and deployed GenAI illustrate the pitfalls of using models that are inadequately trained, trained on low-quality data sets or developed without sufficient subject matter expertise. Technology with a Point of View: Encoding Life Sciences Expertise with AI lays out five key questions life sciences leaders should consider as they look at GenAI adoption expansion from a practical perspective: When is best to launch a new GenAI solution? Should the solution be created from scratch or through partnership with a vendor? What should we be trying to optimize with GenAI? Where do we find ROI? How do we build a data foundation for GenAI? 'GenAI has groundbreaking potential in terms of business value, as it amplifies the capacity of non-technical personas within life sciences organizations to deliver exponential impact,' said Rajeev Rangachari, Chief Technology Officer at Trinity Life Sciences. 'Use cases that weren't viable in the past due to cost or capability limitations have begun gaining traction for specific functions within life sciences, such as Medical Affairs, Value and Access, or Field Sales.' 'To unlock the transformative opportunity of GenAI, two elements need to connect: leadership that imagines possibilities across business and technical worlds, and applications that bring the potential of AI to business needs,' added Jonathan Jenkins, Head of Digital & AI Solutions at Trinity Life Sciences. Life sciences executives are welcome to download the white paper here. About Trinity Life Sciences With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit
IOL News
20-05-2025
- Health
- IOL News
The brain's betrayal: unpacking addiction's rewiring and the rocky road to recovery
Recovery from addiction requires more than just willpower; it necessitates a desire for change and a supportive environment. Image: Pexels. In a comprehensive study encompassing over 25 years of research, scientists at Vilnius University's Life Sciences Centre have provided groundbreaking insights into the biological foundations of addiction. Led by Professor Valentina Vengelienė, the research underscores addiction as a brain disorder influenced by both genetic and environmental factors, offering essential perspectives on why overcoming addiction is a hard journey for many. At the core of the findings is the alarming way psychoactive substances, such as opioids, cocaine, and nicotine, hijack the brain's natural reward system, overriding behavioural control and inducing changes within neural networks that cannot simply be reversed by willpower alone. "When addiction develops, the brain undergoes irreversible changes that lead to a loss of behavioural control," Vengelienė warns. "Addiction can be identified through at least three prominent symptoms, including an intense craving for the substance, difficulties in abstaining and neglect of social responsibilities." Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Advertisement Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Next Stay Close ✕ Opioids, cocaine and nicotine are the substances that most quickly lead to addiction. Valentina Vengelienė, Professor from the Life Sciences Center of Vilnius University (VU), warns that it is best not to dabble with these substances at all. Image: Supplied. Why do people consistently seek out pleasurable experiences? Vengelienė points out that an intrinsic drive to enjoy pleasurable moments is not unique to humans, but also prevalent in various animal species. However, humans benefit from a more permissive lifestyle, free from the constant needs of survival, which can make indulging in substances intoxicatingly tempting. "The modern human doesn't need to spend hours searching for food or evading threats, which allows indulgence in substances," she explained. The research delves into the mechanics of how the brain links specific cues, sights, sounds or smells with memories of rewards or dangers. These connections can provoke cravings, even when one isn't consciously seeking a substance. "The brain's reward system is built to reinforce behaviours necessary for survival," said Vengelienė, highlighting how neurotransmitters like dopamine play a pivotal role in creating strong associations for repeating certain actions. She stresses that psychoactive substances activate the brain's reward centres in a way that vastly exceeds natural stimuli, making them incredibly potent. "Natural rewards control us, which is why sticking to a diet is a herculean task for many. For those with a genetic predisposition to addiction, this challenge becomes infinitely harder," she shares. In essence, the pleasurable feelings associated with substances can overpower instincts of self-preservation, distancing individuals from the realities of health risks and social responsibilities. The research indicates a delicate balance between genetics and environmental factors in determining whether an individual will develop an addiction, with both factors contributing roughly 50% to the risk. Vengelienė notes that an individual's family history with substance use and the trauma experienced during childhood could potentially influence the likelihood of developing a dependency. "Even exposure in the womb can affect the neural pathways that govern behaviour," she adds. Despite the awareness that not everyone who tries psychoactive substances becomes addicted, Vengelienė cautions against experimentation. "Approximately 10 to 15% of individuals who experiment with drugs find themselves developing an addiction," she says, highlighting the risks even in casual experimentation. Recognising addiction involves assessing behavioural patterns such as a loss of control, inability to delay usage, and a loss of interest in usual activities. Vengelienė indicates that long-term substance abuse leads to physical changes in the brain, particularly in areas that govern decision-making. "These structural changes compromise an individual's ability to control their addiction and navigate the repercussions of substance use," she adds She states that overcoming addiction isn't solely about willpower. It requires a willingness to seek help and engage in a comprehensive recovery strategy that integrates social support. "Social interaction serves as a crucial natural reward that can, under certain circumstances, outweigh the gains provided by addictive substances." However, she urges that a radical lifestyle change is paramount for recovery. "The established routine of pursuing substances becomes ingrained, fundamentally altering brain structure and neural networks." Transforming such behaviours within the same environment is challenging, making it vital for individuals to seek supportive networks and constructive changes in their lives.
Yahoo
17-05-2025
- Business
- Yahoo
Applied DNA Sciences Second Quarter 2025 Earnings: Misses Expectations
Net income: US$20.6m (up from US$4.63m loss in 2Q 2024). EPS: US$11.63 (up from US$265 loss in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates. Looking ahead, revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Performance of the American Life Sciences industry. The company's shares are down 18% from a week ago. Don't forget that there may still be risks. For instance, we've identified 5 warning signs for Applied DNA Sciences (4 shouldn't be ignored) you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
National Post
14-05-2025
- Business
- National Post
Ecolab Life Sciences Opens New State-of-the-Art Bioprocessing Applications Laboratory in Pennsylvania, US
Article content ST. PAUL, Minn. — Ecolab Life Sciences has officially opened its new US Bioprocessing Applications Laboratory in King of Prussia, Pennsylvania. Article content Article content The new facility is designed to support biopharma customers with applications and process development for the purification of biotherapeutic molecules, providing comprehensive technical support to biopharmaceutical companies and contract manufacturers operating from small-scale to full commercial production. This new development location is well positioned in the Eastern U.S., close to many large pharmaceutical operations and a hub of bioprocessing innovation. Article content The lab is equipped with high-throughput process development tools and manufacturing scale chromatography columns, enabling biotech firms to receive turnkey support for process development. Large biopharma companies can utilize the applications lab throughout the entire development cycle, from early to late stage and commercialization; including characterizing alternative resins to help reduce manufacturing costs and support with regulatory submissions. Article content 'Our new Bioprocessing Applications Lab marks a significant milestone in our ability to be a global technical partner to our customers around the world,' said Jennifer Sorrells, Ph.D., vice president of research and development, Ecolab Life Sciences. 'This facility demonstrates our commitment to delivering best-in-class bioprocessing solutions by pairing Ecolab's innovative resin toolbox with deep domain expertise to optimize the purification process. We are dedicated to empowering our customers to accelerate the delivery of life-saving therapies to market.' Article content Biopharma and contract manufacturing organizations are already leveraging Ecolab's Bioprocessing Applications Lab to help accelerate speed and enhance manufacturing efficiencies through lifecycle studies. The lab can initiate studies and deliver results within weeks, facilitating a faster route to market while providing customers with access to raw data and bench-level operations for transparency and collaboration. Article content The new lab complements Ecolab's existing European Applications and Research & Development Lab, in Wales, U.K., and is part of the Ecolab Life Sciences Pharma Center of Excellence, a multi-million dollar investment which also includes an interactive learning space, The Xchange customer experience center, and an API (Active Pharmaceutical Ingredient) and excipient manufacturing facility. Article content A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on more than a century of innovation, Ecolab has annual sales of $16 billion, employs approximately 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab's innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, high tech, life sciences, hospitality and industrial markets. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
Yahoo
12-05-2025
- Business
- Yahoo
Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025
Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025 Männedorf, Switzerland, May 12, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today provided a qualitative update on its performance for the first quarter of March 12, 2025, Tecan indicated a decline in sales in local currencies for the first half of the year. In line with expectations, sales in the first quarter declined within a mid-single-digit percentage range in local currencies. The Life Sciences Business segment delivered a solid performance, with sales in local currencies close to the prior-year level. This development was supported by increased sales into the clinical diagnostics segment, particularly for genomic testing, as well as recovering consumables sales. As expected, the Partnering Business segment recorded a slightly larger decline than the Group overall, mainly reflecting the timing of customer orders, with customers forecasting a higher volume of sales for the second half of the year. Notably, within this segment, sales of in-vitro diagnostics systems in the Synergence product line showed positive development. While the key assumptions underlying the full-year 2025 sales outlook remain largely consistent with those communicated on March 12, 2025, Tecan provides the following update: Sales in US academic and governmental accounts continue to be impacted by uncertainty and limited visibility regarding the release of funding; accordingly, the related assumptions remain unchanged for the time being. In China, the market environment has begun to stabilize, and sales performance is currently tracking toward a single-digit decline for the full year. Sales to biopharma customers are beginning to show early signs of recovery, with a more pronounced revenue impact expected in the second half of the year. Tecan continues to see a positive contribution from the strong reception of newly launched products and partnerships in both divisions. Sales expectations for the largest customer remain consistent, with sales projected to range from moderately lower to stable compared to the prior year. Based on business performance in the first quarter and current assumptions for the remainder of the year, Tecan today confirms its sales outlook for full-year 2025. The company continues to expect sales in local currencies to be within a range from a low single-digit percentage decline to low single-digit percentage growth for the full also reiterates its forecast for an adjusted EBITDA margin1 of 17.5% to 18.5% of sales for full-year 2025. Tecan also reiterated its mid-term outlook, in which the company anticipates returning to average organic growth rates in the mid to high single-digit percentage range in local currencies under normal market conditions, while continuously improving profitability. Potential tariff impact and mitigationThe potential impact of recently announced reciprocal tariffs by the US Government is currently assessed as limited for Tecan. The Group has substantial manufacturing capacity in the United States, including a major site for instrument and module production in Morgan Hill, California, as well as local manufacturing capabilities for consumables and reagents. Combined with local service offerings, approximately 50% of Tecan's US revenues are generated from localized operations. For 2025, the impact on EBITDA is estimated to be in the mid- to high-single-digit million Swiss franc range should the higher reciprocal tariff levels announced on April 2, 2025, take effect from July 9, 2025. If the current 10% reciprocal tariff level remains in place for the rest of the year, the impact on EBITDA is estimated to be in the low- to mid-single-digit million Swiss franc range. These estimates do not yet reflect any mitigation measures, which will further reduce the overall impact in a meaningful way. The profitability outlook remains achievable under the current 10% reciprocal tariff level. Should the higher reciprocal tariff levels announced on April 2, 2025, take effect from July 9, 2025, Tecan would fully implement anticipated mitigation measures, reassess the potential impact on its profitability outlook, and provide an update as appropriate. Important new products and partnerships - highlightsTecan continues to drive innovation across both business divisions, with a strong focus on launching promising new products and expanding strategic partnerships. In the first quarter of 2025, significant progress was achieved, with several key highlights outlined below. In January 2025, Tecan officially launched Veya™, a multi-omics liquid handling workstation, at the Society for Laboratory Automation and Screening (SLAS) international conference in San Diego, USA. Veya is designed to overcome key barriers in laboratory automation, providing effortless automation that simplifies workflows and boosts productivity. The new platform has been met with strong interest and positive feedback from both conference attendees and the broader market. As regulatory requirements evolve, Tecan is proactively expanding its specialty diagnostics offering. In the first quarter, Tecan broadened its reagent portfolio through the acquisition of assets related to four ELISA kits, two for in vitro diagnostics and disease monitoring, and two for research use only. Additionally, Tecan announced a partnership with Grifols to develop biomarker panels for specialty diagnostics, leveraging Grifols' single molecule counting (SMC) platform and Tecan's expertise in immunoassays. Tecan's Partnering Business continues to demonstrate the strength of its customer relationships and the depth of its project pipeline across the Synergence, Cavro, and Paramit lines. By leveraging synergies and joint selling across these OEM offerings, Tecan has further enriched its pipeline and secured new manufacturing partnerships in key segments such as life sciences, lab diagnostics, and Medtech. In the first quarter, Tecan secured a manufacturing contract - delivered through its Paramit offering - for a major diagnostic system with a leading global diagnostics company, building on a longstanding Synergence collaboration; the system is already commercially available. Additionally, Tecan expanded its relationship with a life science research customer: having previously supplied Cavro components for a high-throughput proteomics platform, Tecan is now, through its Paramit services, also manufacturing this very platform, which is already commercially available. Key upcoming dates The 2025 Interim Report will be published on August 12, 2025. A Q3 Qualitative Update will be published on October 13, 2025. 1 The adjusted EBITDA (operating profit before depreciation and amortization) excludes restructuring costs as well as acquisition- and integration-related costs. The expectations regarding profitability are based on an average exchange rate forecast for full year 2025 of one euro equaling CHF 0.95 and one US dollar equaling CHF 0.90. About Tecan Tecan ( improves people's lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2024, Tecan generated sales of CHF 934 million (USD 1,062 million; EUR 984 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191). For further information: Tecan GroupMartin BrändleSenior Vice President, Corporate Communications & IRTel. +41 (0) 44 922 84 30 Fax +41 (0) 44 922 88 89 investor@ Attachment Press Release
